ConductScience.org, home

Gene · 4261

CIITA: class II major histocompatibility complex transactivator

12 sourcesgene-search-2026-11-11-0.2.0

Download JSON
Cite this record

ConductScience Library. CIITA: class II major histocompatibility complex transactivator. Genes, record 4261. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/4261

On this page

Gene

Symbol
CIITA
HGNC
Name
class II major histocompatibility complex transactivator
HGNC
NCBI Gene ID
4261
NCBI Gene
HGNC ID
HGNC:7067
HGNC
Ensembl
ENSG00000179583
NCBI Gene
Aliases
C2TA, CIITAIV, MHC2D1, MHC2TA, NLRA
NCBI Gene
Type
protein-coding
NCBI Gene

Proteins1

Reviewed human proteins whose Swiss-Prot entry states the gene.

UniProt entryProteinLengthStructuresGene stated in
P33076MHC class II transactivator1,1300Ensembl, GeneID, HGNC

Source UniProt

Patents33

Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.

PublicationPublishedSEQ ID NOProteinSource
WO 2026222388 A12026-10-2214P33076Espacenet
WO 2026177163 A2026-08-271P33076Espacenet
EP 4782537 A12026-07-292P33076Espacenet
JP 2026500670 A2026-01-0814P33076Espacenet
EP 4641201 A22025-10-294638P33076Espacenet
EP 4641202 A22025-10-294906P33076Espacenet
KR 1020250127134 A2025-08-2614P33076Espacenet
JP 2025517969 A2025-06-124638P33076Espacenet
US 12252699 B22025-03-184P33076Espacenet
KR 1020250017231 A2025-02-044906P33076Espacenet

1 to 10 of 33

See all 33 patents

Drugs0

Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.

None in this release.

Trials0

Trials of those drugs. A trial joins the gene only through a drug that acts on it.

None in this release.

NIH grants2,387

NIH grants whose papers are about the gene, through NIH's grant-paper links.

GrantTitleCIITA papersNewest fiscal year
P30CA008748Cancer Center Support Grant292025
R01AI029564Molecular and Functional Analysis of Innate Immune Receptors202025
P30CA016672Cancer Center Support Grant142025
P30CA016056Roswell Park Cancer Center Support Grant102025
P30CA006973Regional Oncology Research Center72025
P30CA046934University of Colorado Cancer Center Support Grant72025
UL1TR001863Yale Clinical and Translational Science Award72025
P30CA068485Cancer Center Support Grant62025
ZIABC011006Molecular diagnosis and outcome prediction in lymphoma62025
P30CA023074University of Arizona Cancer Center - Cancer Center Support Grant52025

1 to 10 of 2,387Source NIH's project files

See all 2,387 nih grants

Papers3,496

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

TitleJournalYearPMIDFound bySource
Primary central nervous system lymphoma in the molecular era: genomic drivers, liquid biopsy, and targeted therapeutic strategies.Ann Hematol202642814177PubTator, text miningPubMed
The MHC class II transactivator CIITA induction as a potential new tool to develop anti-tumor vaccines and predict the efficacy of immunotherapy.Exp Mol Pathol202642790135PubTator, text miningPubMed
Pre-transplant whole blood transcriptomic profiling identifies mRNAs linked to cirrhosis-associated immune dysfunction as candidate predictors of clinical outcomes after liver transplantation: an exploratory study.
Transpl Int202642729608PubTator, text miningPubMed
Ultrasound‑responsive nano‑contrast agents co‑delivering CIITA ‑siRNA and rapamycin for targeted therapy against Hashimoto thyroiditis.Chin Med J (Engl)202642711270PubTator, text miningPubMed
Major histocompatibility complex class II deficiency in Morocco: a 26-year retrospective cohort study.Front Immunol202642707230PubTator, text miningPubMed
Iron Dyshomeostasis and Divergent Antigen Presentation Remodeling in Bronchiectasis: A Dual-Dataset Transcriptomic Analysis.J Inflamm Res202642670432PubTator, text miningPubMed
Identification of Predictive Biomarkers for Chemoradiotherapy Response in Rectal Cancer.JCO Precis Oncol202642566730PubTator, text miningPubMed
Integrated Immunological Engineering Platform for Scalable Production of iPSC-Derived Megakaryocytes.HLA202642493242PubTator, text miningPubMed
Molecular Pathogenesis and Therapeutic Response of Diffuse Large B Cell Lymphoma Genetic Subtypes.Annu Rev Cancer Biol202642487683PubTator, text miningPubMed
The effect of cohesin mutations on HLA-class II expression in the myeloid leukemia of Down syndrome.Leukemia202642481796PubTator, text miningPubMed

1 to 10 of 3,496

See all 3,496 papers

Sources 12

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
  • GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
  • HGNCCC0
  • NCBI GenePublic domain (US government)
  • NIH's project files and grant-paper linksPublic domain
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
  • GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
  • HGNCCC0: https://www.genenames.org/about/license/
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this gene from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/genes/v1/4261

GET https://conductscience.org/api/genes/v1/4261/patents?page=2